Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Reports Second Quarter 2019 Results
CMS Assigns New J Code for SINUVA and PROPEL, Effective October 1 MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 1, 2019-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the second
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2019 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 15, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release second quarter financial results on August 1, 2019 .
View HTML
Toggle Summary Intersect ENT Reports First Quarter 2019 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--May 6, 2019-- Intersect ENT ® , Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2019 .
View HTML
Toggle Summary Intersect ENT to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 25, 2019-- Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will participate in the 2019 Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019 at the Encore Hotel in Las Vegas , including a Q&A session at 1:40 p.m.
View HTML
Toggle Summary Intersect ENT to Report First Quarter 2019 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 23, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it will release first quarter financial results on May 6, 2019 .
View HTML
Toggle Summary Intersect ENT Reports Fourth Quarter and Full Year 2018 Results
ENCORE Clinical Study Completed, Primary Endpoints Met MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 25, 2019-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth
View HTML
Toggle Summary Intersect ENT to Present at the 8th Annual SVB Leerink Global Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 12, 2019-- Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at the Lotte New York Palace in New York City , and will present in a
View HTML
Toggle Summary Intersect ENT to Report Fourth Quarter and Year 2018 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 11, 2019-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release fourth quarter and year 2018 financial results on February 25, 2019 .
View HTML
Toggle Summary Intersect ENT Reports Preliminary Fourth Quarter and Full Year 2018 Revenue
MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 7, 2019-- Intersect ENT, Inc.  (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the fourth quarter and full year ended  December 31,
View HTML
Toggle Summary Intersect ENT Announces First Patient Enrolled in ASCEND Study of Investigational Drug-Coated Sinus Balloon
Innovative Drug-Device Combination Will Leverage Company’s Expertise in Localized Drug Delivery MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 17, 2018-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the
View HTML